surmount-1 tirzepatide trial weight loss non-diabetic once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Flow of Participants in the

Moving beyond food noise to drug noise, GLP-1s are quieting the roar of addiction. Reference: Metabolic medicines and addiction: what GLP-1 receptor agonists might add to substance use care by Fares Qeadan, 4 March 2026, BMJ

However, some high-deductible health plans, health savings accounts (HSAs), and flexible spending accounts (FSAs) may allow tirzepatide costs as eligible medical expensesverify with your plan before initiating treatment

Elevate energy, improve endurance, and speed up recovery with targeted performance injections like B12, L-Carnitine, and Amino Blends

Those looking for longer-lasting results may want to consider weight loss surgery, like a gastric sleeve